Olaparib, Durvalumab and UV1 in Relapsed Ovarian Cancer
Status:
Not yet recruiting
Trial end date:
2026-06-15
Target enrollment:
Participant gender:
Summary
This prospective, multicenter, open-label, randomized phase II maintenance study is
evaluating the efficacy of UV1-olaparib-durvalumab combination as maintenance therapy after
platinum combination therapy for BRCAwt patients with relapsed ovarian cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Nordic Society of Gynaecological Oncology - Clinical Trials Unit
Collaborators:
Arbeitsgemeinschaft Gynaekologische Onkologie Austria Belgian Gynaecological Oncology Group European Network of Gynaecological Oncological Trial Groups (ENGOT) Hellenic Cooperative Oncology Group North Eastern German Society of Gynaecological Oncology